Lipocine (LPCN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Lipocine (LPCN) is Neutral.

The composite score behind that read is -0.15, weighing +0.07 of bullish evidence against -0.37 bearish.

Lipocine last closed at $1.72, -10.88% on the session.

Against the IVW growth benchmark the position is -11.68% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for LPCN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Lipocine in the 15th percentile on return on equity, where 100 is best.

Lipocine is classified under Health Care / Pharmaceuticals, with a market capitalisation of $15.91M.

StockMap tracks Lipocine as the 125th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Lipocine ranks 95th of 151 in the group, against a group median of -0.08.